Professor Dirk Reinhardt is a pediatrician and internationally recognized specialist in pediatric hematology and oncology. His work focuses on acute myeloid leukemia, translational research, clinical trials, and improved care for seriously ill children. He led the AML-BFM Study Group for 16 years. Reinhardt has authored 374 peer-reviewed publications, holds an h-index of 77, and contributes extensively to international professional societies and collaborative networks. He was director and full-professor at the University Children’s Hospital Essen. Since 2025 he serves as CEO of the Leukemia Institute Frankfurt-Essen.

Professor Dirk Reinhardt is a pediatrician and internationally recognized specialist in pediatric hematology and oncology. His work focuses on acute myeloid leukemia, translational research, clinical trials, and improved care for seriously ill children. He led the AML-BFM Study Group for 16 years. Reinhardt has authored 374 peer-reviewed publications, holds an h-index of 77, and contributes extensively to international professional societies and collaborative networks. He was director and full-professor at the University Children’s Hospital Essen. Since 2025 he serves as CEO of the Leukemia Institute Frankfurt-Essen.